# Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer

> **NCT02898207** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 28 (actual)

## Conditions studied

- Metastatic High Grade Fallopian Tube Serous Adenocarcinoma
- Metastatic Malignant Solid Neoplasm
- Metastatic Primary Peritoneal Serous Adenocarcinoma
- Metastatic Triple-Negative Breast Carcinoma
- Platinum-Resistant Fallopian Tube Carcinoma
- Platinum-Resistant Ovarian Carcinoma
- Platinum-Resistant Primary Peritoneal Carcinoma
- Recurrent Breast Carcinoma
- Recurrent High Grade Fallopian Tube Serous Adenocarcinoma
- Recurrent High Grade Ovarian Serous Adenocarcinoma
- Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma
- Recurrent Triple-Negative Breast Carcinoma
- Refractory Fallopian Tube Serous Adenocarcinoma
- Refractory Ovarian Serous Adenocarcinoma
- Refractory Primary Peritoneal Serous Adenocarcinoma
- Refractory Triple-Negative Breast Carcinoma
- Unresectable High Grade Fallopian Tube Serous Adenocarcinoma
- Unresectable Malignant Solid Neoplasm
- Unresectable Primary Peritoneal Serous Adenocarcinoma

## Interventions

- **DRUG:** Olaparib
- **DRUG:** Onalespib

## Key facts

- **NCT ID:** NCT02898207
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-19
- **Primary completion:** 2020-07-29
- **Final completion:** 2022-01-14
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2023-04-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02898207

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02898207, "Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02898207. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*